EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南 2020 更新:筛查、诊断与根治性局部治疗
该指南由 EAU 联合 EANM、ESTRO、ESUR、SIOG 制定,基于 2016–2020 年文献更新,针对临床局限性前列腺癌的筛查、诊断和根治性局部治疗给出推荐。核心推荐包括风险适应筛查、多参数 MRI 避免不必要活检、靶向联合系统活检、低危患者主动监测、中危患者考虑中度大分割放疗等。
要点
- 风险适应筛查一般从 50 岁开始,高危男性从 45 岁、BRCA 突变携带者从约 40 岁开始。
- 推荐多参数 MRI 以避免不必要的活检;活检时应提供靶向联合系统活检。
- 低危患者应始终讨论主动监测,部分有利 ISUP 2 的中危患者也可考虑。
核心结论
- 2020 版指南总结了临床局限性前列腺癌筛查、诊断、分期和局部治疗的最新证据与建议,体现多学科管理特性。
研究设计与样本
- 由 EAU、EANM、ESTRO、ESUR、SIOG 联合制定的指南,证据检索覆盖 2016 至 2020 年新数据,并对每条推荐添加强度评级。
主要发现
- 建议采用风险适应策略识别可能发生前列腺癌的男性,一般从 50 岁开始并基于个体化预期寿命。
- 风险适应筛查应提供给从 45 岁开始的高危男性以及 BRCA 突变携带者(主要是 BRCA2),后者从约 40 岁开始。
- 推荐使用多参数磁共振成像以避免不必要的活检;进行活检时,必须提供靶向联合系统活检。
- 目前没有常规使用组织生物标志物的位置;PSMA PET-CT 是最敏感的分期方法,但缺乏结局获益仍是主要局限。
- 低危患者以及部分有利 ISUP 2 病变的选定中危患者应始终讨论主动监测。
关键数值与推荐
- 一般男性从 50 岁开始风险适应筛查,高危男性从 45 岁开始,BRCA 突变携带者从约 40 岁开始。
- 推荐多参数 MRI 以避免不必要的活检;活检时提供靶向联合系统活检。
- 中危患者强烈推荐考虑中度大分割放疗。
- cN1 前列腺癌患者应接受局部治疗联合长期激素治疗。
临床怎么用
- 对一般男性从 50 岁开始基于个体化预期寿命进行风险适应筛查,高危男性和 BRCA 突变携带者分别从 45 岁和约 40 岁开始。
- 使用多参数 MRI 评估以减少不必要的活检,活检时采用靶向联合系统活检。
- 低危和部分有利 ISUP 2 中危患者应讨论主动监测,中危患者可考虑中度大分割放疗。
- cN1 患者应接受局部治疗联合长期激素治疗。
局限性
- 部分新治疗选项的支持证据尚不够强,不足以提供推荐,因此需要持续更新。
- PSMA PET-CT 虽为最敏感分期方法,但缺乏结局获益是主要限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa). EVIDENCE ACQUISITION: The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence. EVIDENCE SYNTHESIS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment. CONCLUSIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management. PATIENT SUMMARY: Updated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them.
引用
- Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020. PMID: 33172724. doi:10.1016/j.eururo.2020.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。